ALPS Medical Breakthrough... (SBIO)
27.09
-1.43 (-5.01%)
At close: Apr 01, 2025, 3:59 PM
27.05
-0.17%
After-hours: Apr 01, 2025, 04:59 PM EDT
-5.01% (1D)
| Bid | 26.98 |
| Market Cap | 89.39M |
| AUM | 98.18M |
| NAV | 32.19 |
| EPS (ttm) | n/a |
| PE Ratio (ttm) | n/a |
| Shares Out | 3.3M |
| Inception Date | Dec 30, 2014 |
| Ask | 27.07 |
| Volume | 7.49K |
| Open | 28.44 |
| Previous Close | 28.52 |
| Day's Range | 27.02 - 28.44 |
| 52-Week Range | 27.02 - 42.73 |
| Holdings | 103 |
| Expense Ratio | 0.50% |
About SBIO
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
Asset Class Equity
Ticker Symbol SBIO
Inception Date Dec 30, 2014
Provider SS&C
Website Fund Home Page
Top 10 Holdings 35.35% of assets
| Name | Symbol | Weight |
|---|---|---|
| Alkermes Plc | ALKS | 4.66% |
| Verona Pharma Plc | VRNA | 4.66% |
| Axsome Therapeutics,... | AXSM | 4.60% |
| Ptc Therapeutics, In... | PTCT | 3.57% |
| Zai Lab Limited | ZLAB | 3.36% |
| Avidity Biosciences,... | RNA | 3.15% |
| Rhythm Pharmaceutica... | RYTM | 2.99% |
| Akero Therapeutics, ... | AKRO | 2.88% |
| Crinetics Pharmaceut... | CRNX | 2.75% |
| Protagonist Therapeu... | PTGX | 2.73% |
Dividends Dividend Yield 3.52%
| Ex-Dividend | Amount | Payment Date |
|---|---|---|
| Dec 19, 2024 | $1.1740 | Dec 26, 2024 |
| Dec 21, 2023 | $0.0711 | Dec 27, 2023 |
| Dec 19, 2019 | $0.0158 | Dec 27, 2019 |
| Dec 20, 2018 | $0.7841 | Dec 27, 2018 |
| Dec 21, 2017 | $0.5795 | Dec 28, 2017 |
